Translating membrane proteins into therapeutics; from bedside to bench

将膜蛋白转化为治疗药物；

• 批准号: nhmrc : 1150083
• 负责人: Prof Arthur Christopoulos
• 金额: $ 631.19万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Program Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/translating-membrane-proteins-bedside-bench/1321096
• 关键词: Translating; membrane; proteins; into; therapeutics

Membrane proteins are the principal gatekeepers for control of cellular response, with G protein-coupled receptors (GPCRs) the largest family of cell surface proteins. These proteins are critically important for pathophysiological control, and are a major target for drug discovery. Nonetheless drug attrition due to lack of clinical efficacy remains high. We are combining cell biology, clinical management and drug discovery science to enable more effective therapeutic translation.

膜蛋白是控制细胞反应的主要守门人，其中G蛋白偶联受体（GPCR）是细胞表面蛋白的最大家族。这些蛋白质对于病理生理学控制至关重要，并且是药物发现的主要靶标。尽管如此，由于缺乏临床疗效导致的药物损耗仍然很高。我们将细胞生物学、临床管理和药物发现科学相结合，以实现更有效的治疗转化。